Professor Mary M Reilly md, frcp, frcpi
MRC Centre for Neuromuscular Disease and Dept. of Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Professor Mary M. Reilly graduated from University College Dublin in 1986, received her MD in 1996, FRCP in 2002 and her FRCPI in 2003. She was appointed a consultant neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square in 1998 and a Professor of Clinical Neurology at UCL in 2010. She leads the peripheral nerve clinical service in the National Hospital for Neurology and Neurosurgery, leads a research group in the MRC centre for Neuromuscular Diseases in UCL Queen Square Institute of Neurology (ION) and is head of the Division of Clinical Neurology in ION. She has a longstanding interest in the clinical management and research in the inherited peripheral neuropathies and runs a research program encompassing gene identification, pathogenetic studies, natural history studies, development of outcome measures and conducting clinical trials in inherited neuropathies. Professor Reilly is a co-director of both the UCL MRC Centre for Neuromuscular Diseases and the NIH Inherited Neuropathy Consortium. She is the immediate Past President of the Association of British Neurologist (ABN), a past President of the British Peripheral Nerve Society (BPNS), and a past President of the international Peripheral Nerve Society (PNS).
MB BS PhD FRACP
Stephen Reddel is a staff specialist neurologist at Concord Repatriation & General Hospital Sydney, and consultant neurologist at the Brain & Mind Research Institute, University of Sydney. He trained in neurology at Royal Prince Alfred Hospital, Sydney, and at the Radcliffe Infirmary, Oxford, and has a PhD in the immunology of the Anti-Phospholipid Syndrome.
He heads the neuroimmunology clinic at Concord Hospital, which specialises in the safe treatment of neurological conditions requiring immunotherapy, including multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and a host of rarer diseases.
He has a longstanding interest in clinical safety. This focus on safety has also included www.immunosuppressionscreen.net , a publically available tool for the safe application of immunosuppression, and in 2014 the Alemtuzumab in MS Safety Study (AMS3), which lead to the development of Bloodwatch and Medical Safety Systems, a multinational medical IT safety company. Their technology enables the automated monitoring of patients requiring regular pathology tests for defined abnormalities or changes in results, substantially improving compliance, notification of abnormalities and reducing workload.
Dr Reddel’s academic appointment is Associate Professor, Sydney University where he has been involved in the neurology course development, ensuring standards of institutional sartorial elegance, online lectures and teaching of medical students, post graduate clinical training and post graduate research student supervision.
He has research interests in myasthenia gravis, examining the function of anti-MuSK antibodies and the homeostasis of the neuromuscular junction; in neuroimmunology and MS, and in neurogenetics including the muscular dystrophies and inherited neuropathies. The neuromuscular junction laboratory is located at Sydney University in collaboration with Dr Bill (William) Phillips. Funding support in the last 5 years has included NH&MRC and the muscular dystrophy associations of the USA and NSW. He has published in journals including Brain, Annals of Neurology and Current Opinion in Neurology in this period.